
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is positioned for sustained fundamental outperformance because multiple growth engines are now compounding at once, led by Cardiac Ablation Solutions, which surpassed $2B in trailing 12-month revenue as of September 2026 and is expected to keep driving share gains in electrophysiology. The broader portfolio adds optionality through renal denervation, Altaviva, Hugo robotics, AVIM, CathWorks, and recent acquisitions, supporting a modeled >5% annual top-line growth rate through 2030 versus consensus closer to 4%-5%. Its valuation remains reasonable near a 5-year average P/E, while mix shift toward higher-margin therapies and potential reimbursement expansion should support earnings upside and margin expansion.
Bears say
Medtronic is facing a mixed but ultimately fragile setup, with FY27 guidance only modestly improved and still dependent on mid-single-digit organic growth, FX headwinds, and EPS of just $5.94-$6.00 despite a revenue outlook of roughly $38.9B-$39.2B. The bearish case is driven by slower product growth, competitive encroachment in key segments, potential regulatory delays, and macro weakness, while tariff relief is not yet embedded in guidance. Recent investments in Pi-Cardia and Cornerstone Robotics may broaden the portfolio, but they also underscore strategic pressure around structural heart and robotics, raising questions about the durability of Hugo and execution quality.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Medtronic (MDT) Forecast
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares